Prelude Therapeutics Announces Poster With Preclinical Data On Its Oral KAT6A Selective Degrader Accepted For Presentation At American Association For Cancer Research Annual Meeting 2026

Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced that a poster featuring preclinical data on its oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2026, scheduled for April 17-22. The company is developing first-in-class KAT6A selective degraders and plans to file an IND in mid-2026, with a phase 1 study expected to begin in the second half of 2026.